FDA advisers support efficacy and safety of GSK’s RSV vaccine with more confidence than Pfizer rival
FDA advisers endorsed the safety and efficacy of GSK’s respiratory syncytial virus (RSV) vaccine in older adults, setting up a final mad dash with Pfizer as both companies eye the regulatory finish line with their promising new vaccines.
